Safety and efficacy of daclizumab beta in patients with relapsing multiple sclerosis in a 5-year open-label study (EXTEND): final results following early termination

por Kappos, Ludwig, Cohan, Stanley, Arnold, Douglas L., Robinson, Randy R., Holman, Joan, Fam, Sami, Parks, Becky, Xiao, Shan, Castro-Borrero, Wanda
Publicado 2021

Long-term safety and efficacy of daclizumab beta in relapsing–remitting multiple sclerosis: 6-year results from the SELECTED open-label extension study

por Gold, Ralf, Radue, Ernst-Wilhelm, Giovannoni, Gavin, Selmaj, Krzysztof, Havrdova, Eva Kubala, Montalban, Xavier, Stefoski, Dusan, Sprenger, Till, Robinson, Randy R., Fam, Sami, Smith, Jonathan, Chalkias, Spyros, Giannattasio, Giorgio, Lima, Gabriel, Castro-Borrero, Wanda
Publicado 2020

Lymphocyte reconstitution after DMF discontinuation in clinical trial and real-world patients with MS

por Chan, Andrew, Rose, John, Alvarez, Enrique, Bar-Or, Amit, Butzkueven, Helmut, Fox, Robert J., Gold, Ralf, Gudesblatt, Mark, Haartsen, Jodi, Spelman, Tim, Wright, Katy, Ferraro, Diana, Sola, Patrizia, Hodgkinson, Suzanne, Kalincik, Tomas, Lechner-Scott, Jeannette, McGuigan, Christopher, Spach, Karen, Chen, Chongshu, Fam, Sami, Wu, Fan, Miller, Catherine
Publicado 2020